<DOC>
	<DOCNO>NCT03079089</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) treatment option significant chance heal lymphoid hematological refractory multiple relapse chemotherapy . However , patient indication allo-HSC benefit two limitation : toxicity treatment graft shortage available . For patient refractory relapse indication allo-HSC , use combinaison SET follow reduced-intensity allo-HSC ( RIC ) show interesting result . A post-transplant immune modulation prophylactic injection donor lymphocyte ( PDLI ) show effectiveness decrease risk relapse low toxicity chemotherapy</brief_summary>
	<brief_title>Sequential Conditioning Haploidentical Transplantation Hematopoietic Stem Cells Patients With Relapsed Refractory Lymphoid Hematological Disorders</brief_title>
	<detailed_description />
	<mesh_term>Hematologic Diseases</mesh_term>
	<criteria>Patients indication alloHSC lymphoid hematological malignancy like Hodgkin 's lymphoma , non hodgkin 's lymphoma b cell ( mantle follicular , diffuse large cell , marginal zone , MALT ) T ( peripheral T whithout specificity , anaplasic , angioimmunoblastic , natural killer cell , gamma / delta T cell , Sezary 's syndrome , primitive cutaneous T ) , prolymphocytic leukemia , chronic lymphocytic leukemia , waldenström 's disease therapeutic strategie combine sequential chemotherapy follow reducedintensity conditioning ( SET RIC + PDLI ) decide Patients least partial response ( standard criterion ) rescue treatment day evaluation 1 month conditioning Advanced age ≥ 18 &lt; 60 year Cardiac ejection fraction leave ventricle ≥ 45 % Lung function free diffusion capacity carbon monoxide ≥ 50 % predict value Creatinine clearance ≥ 50 ml / min depend CKDEPI formula Availability HLA haploidentical donor family Collection nonopposition Invasion uncontrolled CNS Availability HLA identical family donor agree donate hematopoietic stem cell OR nonrelated donor HLAcompatible 10/10 HLAA allele , B , C , DRB1 DQB1 available ready give 4 week make decision allograft Presence patient HLAspecific antibody direct antigen HLA haploidentical donor family Karnofsky score &lt; 70 % Patient HIV positive Hepatitis B C chronic active Uncontrolled infection time start pack Contraindication use treatment provide protocol Previous history alloHSC No beneficiary social security scheme . life expentancy estimate less 1 month investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Allogenic cell stem transplant</keyword>
	<keyword>Sequential chemotherapy</keyword>
	<keyword>Haploidentical transplant</keyword>
</DOC>